These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7568925)

  • 1. [Phosphodiesterase inhibitor: griseolic acid, its' derivatives and their biological activities].
    Kaneko M; Yamazaki M
    Tanpakushitsu Kakusan Koso; 1995 Jul; 40(10):1268-76. PubMed ID: 7568925
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on griseolic acid derivatives. I. Synthesis of substituted derivatives of griseolic acid at the N1, C6, C2' or C7' position and their biological activities.
    Kaneko M; Murofushi Y; Kimura M; Yamazaki M; Iijima Y
    Nucleic Acids Symp Ser; 1985; (16):89-92. PubMed ID: 3003711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Griseolic acid, an inhibitor of cyclic adenosine 3',5'-monophosphate phosphodiesterase. I. Taxonomy, isolation and characterization.
    Nakagawa F; Okazaki T; Naito A; Iijima Y; Yamazaki M
    J Antibiot (Tokyo); 1985 Jul; 38(7):824-9. PubMed ID: 2993218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
    Manallack DT; Hughes RA; Thompson PE
    J Med Chem; 2005 May; 48(10):3449-62. PubMed ID: 15887951
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on griseolic acid derivatives. III. Synthesis and biological activities of the adducts of griseolic acid and their base exchanged derivatives.
    Murofushi Y; Kimura M; Kuwano H; Iijima Y; Yamazaki M; Kaneko M
    Nucleic Acids Symp Ser; 1986; (17):45-8. PubMed ID: 3031627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on griseolic acid derivatives. VII. Synthesis and phosphodiesterase inhibitory activity of the C4'-C5' hydrogenated products of griseolic acid and their base-exchanged derivatives.
    Murofushi Y; Kimura M; Kuwano H; Iijima Y; Yamazaki M; Kaneko M
    Chem Pharm Bull (Tokyo); 1988 Oct; 36(10):3760-9. PubMed ID: 2854497
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies on griseolic acid derivatives. VI. Synthesis and phosphodiesterase-inhibitory activity of 6- and N1-substituted derivatives of griseolic acid.
    Murofushi Y; Kimura M; Iijima Y; Yamazaki M; Kaneko M
    Chem Pharm Bull (Tokyo); 1988 Apr; 36(4):1309-20. PubMed ID: 2843300
    [No Abstract]   [Full Text] [Related]  

  • 8. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
    Gupta R; Kumar G; Kumar RS
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of intracellular cAMP evokes activity-dependent release of adenosine in cultured rat forebrain neurons.
    Lu Y; Li Y; Herin GA; Aizenman E; Epstein PM; Rosenberg PA
    Eur J Neurosci; 2004 May; 19(10):2669-81. PubMed ID: 15147301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
    Rose RJ; Liu H; Palmer D; Maurice DH
    Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.
    Zhou L; Thompson WJ; Potter DE
    Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1745-52. PubMed ID: 10393044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
    Manganiello V
    Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
    [No Abstract]   [Full Text] [Related]  

  • 13. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
    Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
    J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro.
    Truss MC; Uckert S; Stief CG; Kuczyk M; Schulz-Knappe P; Forssmann WG; Jonas U
    Neurourol Urodyn; 1996; 15(1):59-70. PubMed ID: 8696357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
    Birk S; Edvinsson L; Olesen J; Kruuse C
    Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on griseolic acid derivatives. IV. Synthesis and phosphodiesterase inhibitory activity of acylated derivatives of griseolic acid.
    Murofushi Y; Kimura M; Iijima Y; Yamazaki M; Kaneko M
    Chem Pharm Bull (Tokyo); 1987 Mar; 35(3):1036-43. PubMed ID: 3038344
    [No Abstract]   [Full Text] [Related]  

  • 17. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular implications in the use of PDE5 inhibitor therapy.
    Maurice DH
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S20-3. PubMed ID: 15224131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between adenosine and the oxatriazole derivative GEA 3175 in platelets.
    Asplund Persson A; Zalavary S; Lindström E; Whiss PA; Bengtsson T; Grenegård M
    Eur J Pharmacol; 2005 Jul; 517(3):149-57. PubMed ID: 15963495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic nucleotide phosphodiesterases. Possible targets for new drugs.
    Polson JB
    J Fla Med Assoc; 1990 Dec; 77(12):1045-6. PubMed ID: 1963437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.